MEDICINAL CANNABIS

What We DO and DON’T like about the proposed CPH Merger

Today Creso Pharma (ASX: CPH | OTC: COPHF) announced its plans to merge with a Canadian listed psychedelics company called Red Light Holland.

CPH to expand US footprint after USOTC listing

The US OTC listing gives Creso Pharma Ltd (ASX: CPH) greater exposure to a deeper capital market as well as greater access and liquidity for North American investors. Further to this, it provide additional opportunities to attract institutional and retail investors and for CPH to expand its investor base in the US.

NTI Begins Autism Clinical Trials for Unique Cannabis Strain

Neurotech International Ltd (ASX: NTI) has begun its first clinical trials on children aged between 5 and 17 years with Autism Spectrum Disorder (ASD) for its unique cannabis strain.

Revenues up 237%: Creso Pharma delivers strong quarter ahead of OTC listing

There were several highlights to come out of the quarterly report released by Creso Pharma (ASX: CPH) today. CPH is enjoying a sustained run this year with revenues up 237% in the lead up to its US listing, which is expected to occur in the coming weeks.

Bod Australia outlines strong revenue growth

Medicinal cannabis, CBD and hemp healthcare products company, Bod Australia Limited (ASX: BDA) has provided its shareholders an update for the Q3FY2021 quarter, ended 31 March 2021.

Halucenex agreement to give CPH another leg up in psychedelics

Creso Pharma’s (ASX: CPH) pending acquisition of Halucenex Life Sciences should prove to be an astute move, with Halucenex continuing to rapidly move towards its goal of developing and licensing psychedelic compounds for the pharmaceutical and nutraceutical markets.

$18M will help CPH progress near-term revenue initiatives

Creso Pharma (ASX: CPH) has received firm commitments to raise $18M, a sum that significantly shores up its balance sheet. CPH will use the funds to progress a number of value accretive opportunities including Phase II and Phase III clinical trial initiatives with target acquisition company Halucenex Life Sciences Inc.

CPH to list on the OTC as it expands North American footprint

Creso Pharma (ASX: CPH) today announced it is listing on the OTC market in the USA. Listing on the OTC is expected to unlock significant shareholder value and provides CPH with access to one of the largest investment markets in the world at nominal cost.

Revenue generating BDA sets its sights on US market

Bod Australia (ASX: BDA) is a cannabis centric healthcare company, with well-branded premium, proven and trusted products within two distinct verticals: Medical Cannabis and CBD and Hemp Consumer products.

NTI secures strategic Cultivation partnership to grow and maintain its medical cannabis

Neurotech International Limited (ASX: NTI) has announced a strategic cultivation partnership with CannaPacific Limited to grow and maintain genetic stock and assist in the development of elite varietal strains through their exclusive licencing agreement.

Neurotech to commence clinical study program this quarter

Following the successful in vitro findings, Neurotech (ASX: NTI) has begun designing a phase I/II study to assess the safety and efficacy of the novel NTI/Dolce strain in a paediatric population.

The CPH Share Price Seems to Have Stabilised – What’s Next?

Today Creso Pharma (ASX: CPH) reported new and follow up Purchase Orders for its animal health medicinal cannabis products totalling over A$345,000.

NTI Days Away from Crucial Lab Results – Can its Cannabis Strain Treat Autism?

Neurotech International Ltd (ASX: NTI) is focused on the clinical applications of unique cannabis strains to treat neurological disorders such as autism and is set to commence human clinical trials early in 2021.

Creso Pharma is a step closer to unlocking Australian market

Creso Pharma Limited (ASX:CPH, FRA:1X8) has today announced obtainment of an exclusive Heads of Agreement with leading natural, sustainable health and lifestyle brand supplier Martin & Pleasance Pty Ltd.

Creso Pharma to benefit from OTC cannabis sales in Australia

The TGA has recommended that CBD products be down-scheduled to schedule 3 medicines in Australia, allowing OTC sales, which should benefit Creso Pharma (ASX: CPH).

What does a Kamala Harris Vice Presidency mean for cannabis legalisation?

Joe Biden announced that Kamala Harris is his pick for Vice President, should he win the upcoming US Presidential election in November. But what could a Biden/Harris ticket mean for cannabis legalization?

No mention of cannabis legalisation at US Democrat National Convention

Despite the pro-cannabis atmosphere in 2019 during the Democrat primaries and Biden's and Harris's evolving stances on cannabis, there were no comments on cannabis legalization in the 2020 DNC.

Podcast: The future of the cannabis industry and what investors should expect

Here to speak with Finfeed today about the ups and downs of the cannabis industry, cannabis in Canada and what he sees is the future of the cannabis industry is COO and director of Embark Health, Mike Curtis.

Are you a sophisticated investor?
Find out more
Please note: Raisebook is a related entity of S3 Consortium Pty Ltd as defined in Section 9 of the Corporations Act 2001.